Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024 - Takeaways - MDSpire

Patterns of Treatment and Outcomes for Patients Diagnosed with Metastatic Pancreatic Adenocarcinoma in the United States, 2019–2024

  • By

  • Rupali Fuldeore

  • Chia Jie Tan

  • Tomomi Kimura

  • Pegah Farrokhi

  • Rachel Yang

  • Connor Willis

  • Carl Asche

  • David Stenehjem

  • July 20, 2026

Share

  • 1

    Approximately 50% of patients with pancreatic cancer present with metastatic disease at diagnosis, with a 5-year survival rate of ~3%.

  • 2

    Among 9,439 patients with metastatic pancreatic adenocarcinoma, 6,279 initiated first-line systemic therapy within 180 days of diagnosis.

  • 3

    The most common first-line regimens were gemcitabine plus nab-paclitaxel (41.5%) and FOLFIRINOX (36.3%).

  • 4

    Median overall survival was longer for patients treated with FOLFIRINOX compared to those treated with Gem-Nab (10.7 vs 7.6 months).

  • 5

    One-third of patients did not receive systemic therapy within 180 days of metastatic diagnosis, indicating potential gaps in access to care.

Original Source(s)

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024

  • by Rupali Fuldeore, Chia Jie Tan, Tomomi Kimura, Pegah Farrokhi, Rachel Yang, Connor Willis, Carl Asche, David Stenehjem

  • July 20, 2026

Related Content

Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade

Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma

Deep learning-based super-resolution dynamic contrast-enhanced radiomics model for predicting NSMP endometrial cancer